Merck KGaA (MRCG.DE), has struck a deal to buy U.S. biotech company SpringWorks Therapeutics (SWTX.O), for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.
April 28, 2025 - 15:12
By Pharos Investment Advisors Comments are Off
Merck KGaA (MRCG.DE), has struck a deal to buy U.S. biotech company SpringWorks Therapeutics (SWTX.O), for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.
November 14, 2024 - 15:35
By Pharos Investment Advisors Comments are Off
Merck & Co. Inc.’s stock fell 3% Thursday, after the drug company beat profit and sales estimates for the third quarter, but lowered guidance due to charges stemming from deals with partners Curon Biopharmaceutical and Daiichi Sankyo.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved